



IC-Diagnostics (ICDx)

Next-generation immunoassays for hormone detection



ICDx develops ultrasensitive non-competitive immunoassays for hormones using proprietary immunocomplex (IC) antibodies

Application

The technology is applicable both for centralized laboratory testing and in decentralized point-of-care settings.

Market assessment

TAM for hormone immunoassays is +5 billion euros globally across the core analytes. Market demand is driven by the need for improved performance, the aging population, and health awareness.

Competitive advantages

ICDx introduces a fundamentally new detection principle for small molecules, enabling a signal proportional to analyte concentration. This results in improved sensitivity, broader dynamic range. The technology is compatible with existing platforms and any small molecule analyte.

IP Status

Our IP strategy focuses on expanding toward platform-level claims for IC-based detection and assay concepts across multiple analyte classes.

Needs

We are seeking strategic partners to support technology validation, assay integration, and commercialization. In addition, we look for co-development and licensing partners for the technology across multiple diagnostic segments.

Project leader

Janne Leivo
jpleiv@utu.fi

The team

- Janne Leivo (PI)
- Teppo Hyytiä (BD)
- Ida Bäckström (R&D)

SPARK
—FINLAND